National Agency for Food & Drug Administration &

Control (NAFDAC)

Registration & Regulatory Affairs (R & R) Directorate

MODULE 2.3
QUALITY OVERALL SUMMARY – Product Dossier (QOS-PD)

Page 1 of 29
INTRODUCTION
Summary of product information:
Non-proprietary name(s) of the finished
pharmaceutical product(s) (FPP)

Proprietary name(s) of the finished

pharmaceutical product(s) (FPP)

International non-proprietary name(s) of the

active pharmaceutical ingredient(s) (API(s)),
including form (salt, hydrate, polymorph)

Applicant name and address

Dosage form

Reference Number(s)

Strength(s)

Route of administration

Proposed indication(s)

Title:
Name:
Contact person responsible for this
Phone:
application
Fax:
Email:

If there are other contacts who should be routinely copied into correspondence for this application they
should also be listed below.

Page 2 of 29
 2.3.S DRUG SUBSTANCE (or ACTIVE PHARMACEUTICAL INGREDIENT (API))
(NAME, MANUFACTURER)

Complete the following table for the option that applies for the submission of API information:

Name of API:
Name of API manufacturer:
Confirmation of API Prequalification document:
 a copy of the confirmation of API Prequalification document should be provided in Module 1, and
□
 summaries of the relevant information should be provided under the appropriate sections (e.g.
S.1.3, S.2, S.3.1, S.4.1 through S.4.4, S.5 and S.7; see Quality guideline).
Certificate of suitability to the European Pharmacopoeia (CEP):
 is a written commitment provided that the applicant will inform NAFDAC in the event that the CEP is
withdrawn and acknowledged that withdrawal of the CEP will require additional consideration of the API
data requirements to support the dossier:
□ yes, □ no;
□  a copy of the most current CEP (with annexes) and written commitment should be provided in
Module 1;
 the declaration of access should be filled out by the CEP holder on behalf of the FPP manufacturer
or applicant to PQTm who refers to the CEP; and
 summaries of the relevant information should be provided under the appropriate sections (e.g.
S.1.3, S.3.1, S.4.1 through S.4.4, S.5, S.6 and S.7; see Quality guideline).
Active pharmaceutical ingredient master file (APIMF):
 a copy of the letter of access should be provided in Module 1; and
□
 summaries of the relevant information from the Open part should be provided under the
appropriate sections; see Section 3.2.S in the Quality guideline.
Active pharmaceutical ingredient pre-qualified by NAFDAC
□
Provide evidence from NAFDAC
Full details in the PD:
□  Summaries of the full information should be provided under the appropriate sections; see Section
3.2.S in the quality guideline.

2.3.S.1 General Information (name, manufacturer)

2.3.S.1.1 Nomenclature (name, manufacturer)

(a) (Recommended) International Non-proprietary name (INN):
(b) Compendial name, if relevant:
(c) Chemical name(s):
(d) Company or laboratory code:
(e) Other non-proprietary name(s) (e.g. national name, USAN, BAN):

Page 3 of 29
 (f) Chemical Abstracts Service (CAS) registry number:

2.3.S.1.2 Structure (name, manufacturer)

(a) Structural formula, including relative and absolute stereochemistry:

(b) Molecular formula:
(c) Relative molecular mass:

2.3.S.1.3 General Properties (name, manufacturer)

(a) Physical description (e.g. appearance, colour, physical state):

(b) Solubilities:

In common solvents:
Quantitative aqueous pH solubility profile (pH 1.2 to 6.8) at 37°C:

Medium (e.g. pH 4.5 buffer) Solubility (mg/ml)

Dose/solubility volume calculation:

(c) Physical form (e.g. polymorphic form(s), solvate, hydrate):
Polymorphic form:
Solvate:
Hydrate:

(d) Other:

Page 4 of 29
 Property
pH
pK
Partition coefficients
Melting/boiling points
Specific optical rotation (specify solvent)
Refractive index (liquids)
Hygroscopicity
UV absorption maxima/molar absorptivity
Other

2.3.S.2 Manufacture (name, manufacturer)

2.3.S.2.1 Manufacturer(s) (name, manufacturer)

(a) Name, address and responsibility (e.g. fabrication, packaging, labelling, testing,
storage) of each manufacturer, including contractors and each proposed production
site or facility involved in these activities:

Name and address API-PQ

Responsibility number/APIMF/CEP
(including block(s)/unit(s)) number (if applicable)

(b) Manufacturing authorization for the production of API(s) and, where available,
certificate of GMP compliance (GMP information should be provided in Module 1):

2.3.S.2.2 Description of Manufacturing Process and Process Controls (name,

manufacturer)
(a) Flow diagram of the synthesis process(es):
(b) Brief narrative description of the manufacturing process(es):
(c) Alternate processes and explanation of their use:
(d) Reprocessing steps and justification:

Page 5 of 29
2.3.S.2.3 Control of Materials (name, manufacturer)

(a) Name of starting material:

(b) Name and manufacturing site address of starting material manufacturer(s):
(c) Summary of the quality and controls of the starting materials used in the
manufacture of the API:

Step / Starting Material Test(s)/method(s) Acceptance criteria

(d) Where the API(s) and the starting materials and reagents used to manufacture the
API(s) are without risk of transmitting agents of animal spongiform
encephalopathies, a letter of attestation confirming this can be found in:

2.3.S.2.4 Controls of Critical Steps and Intermediates (name, manufacturer)

(a) Summary of the controls performed at critical steps of the manufacturing process and
on intermediates:

Step/materials Test(s)/method(s) Acceptance criteria

2.3.S.2.5 Process Validation and/or Evaluation (name, manufacturer)

(a) Description of process validation and/or evaluation studies (e.g. for aseptic
processing and sterilization):

2.3.S.2.6 Manufacturing Process Development (name, manufacturer)

(a) Description and discussion of the significant changes made to the manufacturing
process and/or manufacturing site of the API used in producing comparative
bioavailability or biowaiver, stability, scale-up, pilot and, if available, production scale
batches:

Page 6 of 29
2.3.S.3 Characterisation (name, manufacturer)

2.3.S.3.1 Elucidation of Structure and other Characteristics (name,

manufacturer)

(a) List of studies performed (e.g. IR, UV, NMR, MS, elemental analysis) and conclusion
from the studies (e.g. whether results support the proposed structure):
(b) Discussion on the potential for isomerism and identification of stereochemistry (e.g.
geometric isomerism, number of chiral centres and configurations) of the API
batch(es) used in comparative bioavailability or biowaiver studies:
(c) Summary of studies performed to identify potential polymorphic forms (including
solvates): <including identification of and data on the API lot used in bioavailability studies>
(d) Summary of studies performed to identify the particle size distribution of the API:
<including identification of and data on the API lot used in bioavailability studies>
(e) Other characteristics:

2.3.S.3.2 Impurities (name, manufacturer)

(a) Identification of potential and actual impurities arising from the synthesis,
manufacture and/or degradation:

i. List of API-related impurities (e.g. starting materials, by-products, intermediates,

chiral impurities, degradation products), including chemical name, structure and
origin:

API-related impurity
(chemical name and Structure Origin
descriptor)

ii. List of process-related impurities (e.g. residual solvents, reagents), including

compound names and step used in synthesis:

Page 7 of 29
 Process-related impurity (compound name) Step used in synthesis

(b) Basis for setting the acceptance criteria for impurities:

i. Maximum daily dose (i.e. the amount of API administered per day) for the API,
corresponding to ICH Reporting/Identification/Qualification Thresholds for the
API-related impurities and the concentration limits (ppm) for the process-related
impurities (e.g. residual solvents):

Maximum daily dose for the API: <x mg/day>

Test Parameter ICH threshold or
concentration limit
API-related impurities Reporting Threshold
Identification Threshold
Qualification Threshold
Process-related impurities <solvent 1>
<solvent 2>, etc.

ii. Data on observed impurities for relevant batches (e.g. comparative bioavailability
or biowaiver, stability batches):

Impurity Acceptance Results (include batch number* and use**)

(API-related and Criteria
process-related)

* include strength, if reporting impurity levels found in the FPP (e.g. for comparative studies)
** e.g. comparative bioavailability or biowaiver studies, stability

iii. Justification of proposed acceptance criteria for impurities:

2.3.S.4 Control of the API (name, manufacturer)

Page 8 of 29
2.3.S.4.1 Specification (name, manufacturer)

(a) API specifications of the FPP manufacturer:

Standard (e.g. Ph.Int., Ph.Eur., BP, USP, in-house)

Specification reference number and version
Analytical procedure
Test Acceptance criteria
(Type/Source/Version)
Description
Identification
Impurities
Assay
etc.

2.3.S.4.2 Analytical Procedures (name, manufacturer)

(a) Summary of the analytical procedures (e.g. key method parameters, conditions,
system suitability testing):

2.3.S.4.3 Validation of Analytical Procedures (name, manufacturer)

(a) Summary of the validation information (e.g. validation parameters and results):

See 2.3.R Regional Information for summaries of the validation information (i.e. 2.3.R.2
Analytical Procedures and Validation Information ).

Summarized tabulated methods and validation may be provided in a separate file <provide
reference>.

2.3.S.4.4 Batch Analyses (name, manufacturer)

(a) Description of the batches:

Page 9 of 29
 Date and Use (e.g. comparative
Batch number Batch size bioavailability or
site of production biowaiver, stability)

(b) Summary of batch analyses release results of the FPP manufacturer for relevant
batches (e.g. comparative bioavailability or biowaiver, stability):
Test Acceptance Results
Criteria <batch x> <batch y> etc.
Description
Identification
Impurities
Assay
etc.

(c) Summary of analytical procedures and validation information for those procedures
not previously summarized in 2.3.S.4.2 and 2.3.S.4.3 (e.g. historical analytical
procedures):

2.3.S.4.5 Justification of Specification (name, manufacturer)

(a) Justification of the API specification (e.g. evolution of tests, analytical procedures
and acceptance criteria, differences from officially recognized compendial
standard(s)):

2.3.S.5 Reference Standards or Materials (name, manufacturer)

(a) Source (including lot number) of primary reference standards or reference materials
(e.g. Ph.Int., Ph.Eur., BP, USP, in-house):
(b) Characterization and evaluation of non-official (e.g. not from an officially recognized
pharmacopoeia) primary reference standards or reference materials (e.g. elucidation
of structure, certificate of analysis):
(c) Description of the process controls of the secondary reference standard (comparative
certificate of analysis and IR spectra against primary standard):

2.3.S.6 Container Closure System (name, manufacturer)

(a) Description of the container closure system(s) for the shipment and storage of the
API (including the identity of materials of construction of each primary packaging

Page 10 of 29
 component and a brief summary of the specifications):

Specifications (list parameters e.g.

Packaging component Materials of construction
identification (IR))

(b) Other information on the container closure system(s) (e.g. suitability studies):

2.3.S.7 Stability (name, manufacturer)

2.3.S.7.1 Stability Summary and Conclusions (name, manufacturer)

(a) Summary of stress testing (e.g. heat, humidity, oxidation, photolysis, acid/base): and
results:

Results (e.g. including discussion whether mass

Stress condition Treatment
balance and peak purity are observed)
Heat
Humidity
Oxidation
Photolysis
Acid
Base
Other

(b) Summary of accelerated and long-term testing parameters (e.g. studies conducted):

Storage condition Completed (and

Container closure
Batch number Batch size proposed) testing
(◦C, % RH) system
intervals

Summary of the stability results observed for the above accelerated and long-term
studies:

Page 11 of 29
 Test (limits) Results
Description
Moisture
Impurities
Assay
etc.

(c) Proposed storage statement and re-test period (or shelf-life, as appropriate):

Container closure system Storage statement Re-test period*

* indicate if a shelf-life is proposed in lieu of a re-test period (e.g. in the case of labile APIs)

2.3.S.7.2 Post-approval Stability Protocol and Stability Commitment (name,

manufacturer)

(a) Stability protocol for Primary stability batches (e.g. storage conditions (including
tolerances), batch numbers and batch sizes, tests and acceptance criteria, testing
frequency, container closure system(s)):

Parameter Details
Storage condition(s) (◦C, % RH)
Batch number(s) / batch size(s) <primary batches>
Tests and acceptance criteria Description
Moisture
Impurities
Assay
etc.

Testing frequency
Container closure system(s)

(b) Stability protocol for Commitment batches (e.g. storage conditions (including
tolerances), batch numbers (if known) and batch sizes, tests and acceptance criteria,
testing frequency, container closure system(s):
Parameter Details
Storage condition(s) (◦C, % RH)
Batch number(s) / batch size(s) <not less than three production batches>
Tests and acceptance criteria Description
Moisture

Page 12 of 29
 Parameter Details
Impurities
Assay
etc.

Testing frequency
Container closure system(s)

(c) Stability protocol for Ongoing batches (e.g. storage conditions (including tolerances),
batch sizes and annual allocation, tests and acceptance criteria, testing frequency,
container closure system(s):

Parameter Details
Storage condition(s) (◦C, % RH)
Annual allocation <at least one production batch per year (unless none is produced that
year) in each container closure system >
Tests and acceptance criteria Description
Moisture
Impurities
Assay
etc.

Testing frequency
Container closure system(s)

2.3.S.7.3 Stability Data (name, manufacturer)

(a) The actual stability results should be provided in Module 3.
(b) Summary of analytical procedures and validation information for those procedures
not previously summarized in 2.3.S.4 (e.g. analytical procedures used only for
stability studies):

2.3.P DRUG PRODUCT (or FINISHED PHARMACEUTICAL PRODUCT (FPP))

2.3.P.1 Description and Composition of the FPP

(a) Description of the FPP (in signed specifications):
(b) Composition of the FPP:
i. Composition, i.e. list of all components of the FPP and their amounts on a per unit
basis and percentage basis (including individual components of mixtures prepared
in-house (e.g. coatings) and overages, if any):

Page 13 of 29
Component and quality Function Strength (label claim)
standard (and grade, if
applicable) Quant. per % Quant. per % Quantity %
unit or per unit or per per unit or
mL mL per mL
<complete with appropriate titles e.g. Core tablet (Layer 1, Layer 2, etc. as applicable), Contents of capsule, Powder for
injection>

Subtotal 1
<complete with appropriate title e.g. Film-coating >

Subtotal 2
Total

ii. Composition of all components purchased as mixtures (e.g. colourants, coatings,

capsule shells, imprinting inks):

(c) Description of accompanying reconstitution diluent(s), if applicable:

(d) Type of container closure system used for the FPP and accompanying reconstitution
diluent, if applicable:

2.3.P.2 Pharmaceutical Development

2.3.P.2.1 Components of the FPP

2.3.P.2.1.1 Active Pharmaceutical Ingredient

(a) Discussion of the:

i. compatibility of the API(s) with excipients listed in 2.3.P.1:
ii. key physicochemical characteristics (e.g. water content, solubility, particle size
distribution, polymorphic or solid state form) of the API(s) that can influence the
performance of the FPP:
iii. for fixed-dose combinations, compatibility of APIs with each other:

2.3.P.2.1.2 Excipients
(a) Discussion of the choice of excipients listed in 2.3.P.1 (e.g. their concentrations, their
characteristics that can influence the FPP performance):

Page 14 of 29
2.3.P.2.2 Finished Pharmaceutical Product

2.3.P.2.2.1 Formulation Development

(a) Summary describing the development of the FPP (e.g. route of administration, usage,
optimization of the formulation, etc.):
(b) Information on primary (submission, registration, exhibit) batches including
comparative bioavailability or biowaiver, stability, commercial:

i. Summary of batch numbers:

Batch number(s) of the FPPs used in

<e.g. bioequivalence batch A12345> <e.g.
Bioequivalence or biowaiver
biowaiver batch X12345>
For proportional strength biowaiver: the
bioequivalence batch of the reference strength
Dissolution profile studies
Stability studies (primary batches)
‹packaging configuration I›
‹ packaging configuration II›
‹Add/delete as many rows as necessary›
Stability studies (production batches)
‹ packaging configuration I›
‹ packaging configuration II›
(Add/delete as many rows as necessary)
Validation studies (primary batches) if available
‹ packaging configuration I›
‹ packaging configuration II›
(Add/delete as many rows as necessary)
Validation studies (at least the first three
consecutive production batches)
or code(s)/version(s) for process validation
protocol(s)

Page 15 of 29
 ii. Summary of formulations and discussion of any differences:

Component and Relevant batches

quality standard Comparative Stability Process validation Commercial
(e.g. NF, BP, bioavailability or (2.3.P.1)
Ph.Eur, in-house) biowaiver
<Batch nos. and <Batch nos. and <Batch nos. and <Batch nos. and
sizes> sizes> sizes> sizes>
Theor. % Theor. % Theor. % Theor. %
quantity quantity quantity quantity
per batch per per per
batch batch batch
<complete with appropriate title e.g. Core tablet, Contents of capsule, Powder for injection>

Subtotal 1
<complete with appropriate title e.g. Film-coating >

Subtotal 2
Total

(c) Description of batches used in the comparative in vitro studies (e.g. dissolution) and
in the in vivo studies (e.g. comparative bioavailability or biowaiver), including
strength, batch number, type of study and reference to the data (volume, page):
(d) Summary of results for comparative in vitro studies (e.g. dissolution):

Summary of the multi-point dissolution profiles for the biobatch(es) in three BCS
media across the physiological pH range and the proposed medium if different from
the BCS media:

(e) Summary of any information on in vitro-in vivo correlation (IVIVC) studies (with
cross-reference to the studies in Module 5):
(f) For scored tablets, provide the rationale/justification for scoring:

2.3.P.2.2.2 Overages
(a) Justification of overages in the formulation(s) described in 2.3.P.1:

2.3.P.2.2.3 Physicochemical and Biological Properties

(a) Discussion of the parameters relevant to the performance of the FPP (e.g. pH, ionic
strength, dissolution, particle size distribution, polymorphism, rheological
properties):

Page 16 of 29
2.3.P.2.3 Manufacturing Process Development

(a) Discussion of the development of the manufacturing process of the FPP (e.g.
optimization of the process, selection of the method of sterilization):
(b) Discussion of the differences in the manufacturing process(es) for the batches used
in the comparative bioavailability or biowaiver studies and the process described in
2.3.P.3.3:

2.3.P.2.4 Container Closure System

(a) Discussion of the suitability of the container closure system (described in 2.3.P.7)
used for the storage, transportation (shipping) and use of the FPP (e.g. choice of
materials, protection from moisture and light, compatibility of the materials with the
FPP):
(b) For a device accompanying a multi-dose container, a summary of the study results
demonstrating the reproducibility of the device (e.g. consistent delivery of the
intended volume for the lowest intended dose):

2.3.P.2.5 Microbiological Attributes

(a) Discussion of microbiological attributes of the FPP (e.g. preservative effectiveness

studies):

2.3.P.2.6 Compatibility
(a) Discussion of the compatibility of the FPP (e.g. with reconstitution diluent(s) or
dosage devices, co-administered FPPs):

2.3.P.3 Manufacture

2.3.P.3.1 Manufacturer(s)

(a) Name, address and responsibility (e.g. fabrication, packaging, labelling, testing) of
each manufacturer, including contractors and each proposed production site or
facility involved in manufacturing and testing:

Page 17 of 29
 Name and address
Responsibility
(include block(s)/unit(s))

(b) Manufacturing authorization, marketing authorization and, where available, WHO-

type certificate of GMP (GMP information should be provided in Module 1):

2.3.P.3.2 Batch Formula

Largest intended commercial batch size:

Other intended commercial batch sizes:
<information on all intended commercial batch sizes should be in the QOS-PD>

(a) List of all components of the FPP to be used in the manufacturing process and their
amounts on a per batch basis (including individual components of mixtures prepared in-
house (e.g. coatings) and overages, if any):

Strength (label claim)

Master production document
reference number and version
Proposed commercial batch size(s) (e.g.
number of dosage units)
Quantity per Quantity per Quantity per
Component and quality standard
batch (e.g. batch (e.g. batch (e.g.
(and grade, if applicable)
kg/batch) kg/batch) kg/batch)
<complete with appropriate titles e.g. Core tablet (Layer 1, Layer 2, etc. as applicable), Contents of capsule, Powder for
injection>

Subtotal 1
<complete with appropriate title e.g. Film-coating >

Subtotal 2
Total

Page 18 of 29
2.3.P.3.3 Description of Manufacturing Process and Process Controls
(a) Flow diagram of the manufacturing process:
(b) Narrative description of the manufacturing process, including equipment type and
working capacity, process parameters:
(c) Justification of reprocessing of materials:

2.3.P.3.4 Controls of Critical Steps and Intermediates

(a) Summary of controls performed at the critical steps of the manufacturing process and
on isolated intermediates:

Step
Controls (parameters/limits/frequency of testing)
(e.g. granulation, compression, coating)

Proposed/validated holding periods for intermediates (including bulk product):

2.3.P.3.5 Process Validation and/or Evaluation

(a) Summary of the process validation and/or evaluation studies conducted (including
product quality review(s) where relevant) and/or a summary of the proposed process
validation protocol for the critical steps or critical assays used in the manufacturing
process (e.g. protocol number, parameters, results):

Document code(s) for the process validation protocol(s) and/or report(s) (including
reference number/version/date):

2.3.P.4 Control of Excipients

2.3.P.4.1 Specifications

(a) Summary of the specifications for in-house standard specifications:

Page 19 of 29
2.3.P.4.2 Analytical Procedures

(a) Summary of the analytical procedures for supplementary tests:

2.3.P.4.3 Validation of Analytical Procedures

(a) Summary of the validation information for the analytical procedures for
supplementary tests (where applicable):

2.3.P.4.4 Justification of Specifications

(a) Justification of the specifications (e.g. evolution of tests, analytical procedures and
acceptance criteria, exclusion of certain tests, differences from officially recognized
compendial standard(s)):

2.3.P.4.5 Excipients of Human or Animal Origin

(a) For FPPs using excipients without risk of transmitting agents of animal spongiform
encephalopathies, a letter of attestation confirming this can be found in:
(b) CEP(s) demonstrating TSE-compliance can be found in:

2.3.P.4.6 Novel Excipients

Novel excipients are not accepted in PQTm. See quality guideline for definition.

2.3.P.5 Control of FPP

2.3.P.5.1 Specification(s)

(a) Specification(s) for the FPP:

Page 20 of 29
Standard (e.g. Ph.Int., BP, USP, in-house)
Specification reference number and version
Acceptance criteria Acceptance criteria Analytical procedure
Test
(release) (shelf-life) (type/source/version)
Description
Identification
Impurities
Assay
etc.

2.3.P.5.2 Analytical Procedures

(a) Summary of the analytical procedures (e.g. key method parameters, conditions,
system suitability testing):

2.3.P.5.3 Validation of Analytical Procedures

(a) Summary of the validation information (e.g. validation parameters and results):

2.3.P.5.4 Batch Analyses

(a) Description of the batches:

Strength and Date and Use (e.g. comparative

Batch size bioavailability or biowaiver,
batch number site of production stability)

(b) Summary of batch analyses release results for relevant batches (e.g. comparative
bioavailability or biowaiver, stability):

Acceptance Results
Test
criteria <batch x> <batch y> etc.
Description
Identification

Page 21 of 29
 Acceptance Results
Test
criteria <batch x> <batch y> etc.
Impurities
Assay
etc.

(c) Summary of analytical procedures and validation information for those procedures
not previously summarized in 2.3.P.5.2 and 2.3.P.5.3 (e.g. historical analytical
procedures):

2.3.P.5.5 Characterization of Impurities

(a) Identification of potential and actual impurities:

Degradation product
(code name, chemical name Structure Origin
and compendial name (e.g.
USP RC A) if relevant)

Process-related impurity (compound name) Step used in the FPP manufacturing process

(b) Basis for setting the acceptance criteria for impurities:

i. Maximum daily dose (i.e. the amount of API administered per day) for the API,
corresponding ICH Reporting/Identification/Qualification Thresholds for the
degradation products in the FPP and the concentration limits (ppm) for the
process-related impurities (e.g. residual solvents):

Maximum daily dose for the API: <x mg/day>

Test Parameter ICH threshold or
concentration limit
Degradation product Reporting Threshold
Identification Threshold
Qualification Threshold
Process-related impurities <solvent 1>
<solvent 2>, etc.

ii. Data on observed impurities for relevant batches (e.g. comparative bioavailability
or biowaiver):

Page 22 of 29
 Acceptance Results
Impurity
criteria
(degradation product
<batch no.,
and process-related)
strength, use>

iii. Justification of proposed acceptance criteria for impurities:

2.3.P.5.6 Justification of Specification(s)

(a) Justification of the FPP specification(s) (e.g. evolution of tests, analytical procedures
and acceptance criteria, differences from officially recognized compendial
standard(s)):

2.3.P.6 Reference Standards or Materials

(a) Source (including lot number) of primary reference standards or reference materials
(e.g. Ph.Int., Ph.Eur., BP, USP, in-house) not discussed in 3.2.S.5:
(b) Characterization and evaluation of non-official (e.g. not from an officially recognized
pharmacopoeia) primary reference standards or reference materials (e.g. elucidation
of structure, certificate of analysis) not discussed in 3.2.S.5:
(c) Description of the process controls of the secondary reference standard (comparative
certificate of analysis and IR spectra against primary standard) not discussed in
3.2.S.5:

2.3.P.7 Container Closure System

(a) Description of the container closure systems, including unit count or fill size,
container size or volume:

Description Strength Unit count or fill size Container size

(including materials of (e.g. 60s, 100s etc.) (e.g. 5 ml, 100 ml etc.)
construction)

Page 23 of 29
 (b) Summary of specifications of each primary and functional secondary (e.g. foil
pouches) packaging components:

Specifications
Packaging component
(list parameters e.g. identification (IR))
HDPE bottle
PP cap
Induction sealed liners
Blister films (PVC, etc)
Aluminum foil backing
etc.

(c) Other information on the container closure system(s):

2.3.P.8 Stability

2.3.P.8.1 Stability Summary and Conclusions

(a) Summary of stress testing and results (e.g. photo stability studies, cyclic studies,
freeze-thaw studies, demonstration of stability-indication of purity/assay method(s):
(b) Summary of accelerated and long-term testing parameters (e.g. studies conducted):

Completed (and
Storage conditions Strength and Container closure
Batch size proposed) test
(◦C, % RH) batch number system
intervals

Summary of additional stability studies, if applicable (with reference to data location) <e.g.
studies at intermediate conditions, holding period studies for intermediates and bulk product, transport
studies, in-use studies>:

Page 24 of 29
 Summary of the stability results observed for the above accelerated and long-term studies:

Test Results
Description
Moisture
Impurities
Assay
etc.

(c) Proposed storage statement and shelf-life (and in-use storage conditions and in-use
period, if applicable):

Container closure system Storage statement Shelf-life

2.3.P.8.2 Post-approval Stability Protocol and Stability Commitment

(a) Stability protocol for Primary stability batches (e.g. storage conditions (including
tolerances), batch numbers and batch sizes, tests and acceptance criteria, testing
frequency, container closure system(s)):
Parameter Details
Storage condition(s) (◦C, % RH)
Batch number(s) / batch size(s) <primary batches>
Tests and acceptance criteria Description
Moisture
Impurities
Assay
etc.

Testing frequency
Container closure system(s)

(b) Stability protocol for Commitment batches (e.g. storage conditions (including
tolerances), batch numbers (if known) and batch sizes, tests and acceptance criteria,
testing frequency, container closure system(s) :

Page 25 of 29
Parameter Details
Storage condition(s) (◦C, % RH)
Batch number(s) / batch size(s) <not less than three production batches in each container closure
system>
Tests and acceptance criteria Description
Moisture
Impurities
Assay
etc.
Testing Frequency
Container Closure System(s)

(c) Stability protocol for Ongoing batches (e.g. storage conditions (including tolerances),
number of batches per strength and batch sizes, tests and acceptance criteria, testing
frequency, container closure system(s)):

Parameter Details
Storage condition(s) (◦C, % RH)
Batch size(s), annual allocation <at least one production batch per year (unless none is produced that
year) in each container closure system >
Tests and acceptance criteria Description
Moisture
Impurities
Assay
etc.
Testing frequency
Container closure system(s)

2.3.P.8.3 Stability Data

(a) The actual stability results should be provided in Module 3.

(b) Summary of analytical procedures and validation information for those procedures
not previously summarized in 2.3.P.5 (e.g. analytical procedures used only for
stability studies):
(c) Bracketing and matrixing design and justification for Commitment and/or Ongoing
stability batches, if applicable:

2.3.A APPENDICES

2.3.A.1 Facilities and Equipment (name, manufacturer)

(a) Summary of information on facilities and equipment, in addition to the information

provided in other sections of the submission: Not applicable.

Page 26 of 29
2.3.A.2 Adventitious Agents Safety Evaluation (name, dosage form,
manufacturer)

(a) Summary of the information assessing the risk with respect to potential
contamination with adventitious agents: Not applicable.

2.3.A.3 Excipients

(a) Summary of the details of manufacture, characterization and controls, with cross
references to supporting safety data (nonclinical and/or clinical) for the novel
excipients: Not applicable. Novel excipients are not accepted in PQTm. See quality guideline for
definition.

2.3.R REGIONAL INFORMATION

2.3.R.1 Production Documentation

2.3.R.1.1 Executed Production Documents

(a) List of batches (including strengths) for which executed production documents have
been provided (e.g. comparative bioavailability or biowaiver batches):

2.3.R.1.2 Master Production Documents

(a) The blank master production documents for each strength, proposed commercial
batch size and manufacturing facility should be provided in Module 3.

Page 27 of 29
 2.3.R.2 Analytical Procedures and Validation Information
1ANALYTICAL PROCEDURES AND VALIDATION INFORMATION SUMMARIES

1ATTACHMENT NUMBER:

HPLC Method Summary Volume/Page:

Method name:
Method code: Version and/or Date:
Column(s) / temperature (if other than ambient):
Mobile phase (specify gradient program, if applicable):
Detector (and wavelength, if applicable):
Flow rate:
Injection volume:
Sample solution preparation and concentration
(expressed as mg/ml, let this be termed “A”):
Reference solution preparation and concentration
(expressed as mg/ml and as % of “A”):
System suitability solution concentration
(expressed as mg/ml and as % of “A”):
System suitability tests (tests and acceptance criteria):
Method of quantification (e.g. against API or impurity reference
standard(s)):
Other information (specify):

Page 28 of 29
1ATTACHMENT NUMBER:

Validation Summary Volume/Page:

Analytes:
Typical retention times (RT)
Relative retention times (RTImp./RTAPI or Int. Std.):
Relative response factor (RFImp./RFAPI):
Specificity:
Number of concentrations:
Range (expressed as % “A”):

Linearity / Range:
Slope:
Y-intercept:
Correlation coefficient (r2) :
Conc.(s) (expressed as % “A”):
Accuracy:
Number of replicates:
Percent recovery (avg/RSD):
Precision / Conc.(s) (expressed as % “A”):
Repeatability: Number of replicates:
(intra-assay precision) Result (avg/RSD):
Precision /
Parameter(s) altered:
Intermediate Precision:
Result (avg/RSD):
(days/analysts/equipment)
Limit of Detection (LOD): (expressed as % “A”)
Limit of Quantitation (LOQ): (expressed as % “A”)
Stability of solutions:
Robustness:

Other variables/effects:
Typical chromatograms or spectra may be found in:
Company(s) responsible for method validation:
Other information (specify):

Page 29 of 29